Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- RECEIPT OF C RITICAL LICENSE MARKS SIGNIFICANT MILESTONE FOR F IRST COMMERCIAL-SCALE MANUFACTURING FACILITY FOR ALPHA DART , THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY DESIGNED FOR POTENT AND CONFORMAL TUMOR IRRADIATION -

ALPHA TAU ANNOUNCES RECEIPT OF RADIOACTIVE MATERIAL LICENSE FOR ITS NEW HAMPSHIRE MANUFACTURING FACILITY, ADVANCING TOWARDS COMMERCIAL READINESS

FIRST PATIENT TREATMENT MARKS SUCCESSFUL INITIATION OF MULTI-CENTER PILOT STUDY IN ALPHA DART U.S. PANCREATIC CANCER PROGRAM 

ALPHA TAU SUCCESSFULLY TREATS FIRST PATIENT IN ITS U.S. MULTI-CENTER PANCREATIC CANCER CLINICAL TRIAL

- FDA APPROVAL OF IDE TO CONDUCT A U.S. PILOT STUDY EXPLORING THE USE OF ALPHA DART IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM), A HIGHLY AGGRESSIVE BRAIN CANCER -

ALPHA TAU ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

- INTERIM JAN-2025 RESULTS FROM THREE TRIALS OF ALPHA DART  IN TREATING PANCREATIC CANCER SHARED AT PRESTIGIOUS 2025 ASCO GI SYMPOSIUM AND R&D UPDATE DAY, SHOWING >90% DISEASE CONTROL RATE , IMPRESSIVE OVERALL SURVIVAL IN SUB-GROUP ANALYS E S, AND POSITIVE SAFETY PROFILE -

ALPHA TAU ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

JERUSALEM, MAY 12, 2025 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. (NASDAQ: DRTS , DRTSW ) ("ALPHA TAU" OR THE "COMPANY"), THE DEVELOPER OF THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY ALPHA DART, ANNOUNCED TODAY THAT MR. NADAV KIDRON, THE PRESIDENT, CEO, AND CHAIRMAN OF THE BOARD OF ORAMED PHARMACEUTICALS INC., (ORAMED), HAS BEEN APPOINTED TO THE COMPANY'S BOARD OF DIRECTORS (BOARD). THE APPOINTMENT FOLLOWS THE RECENT CLOSING OF A STRATEGIC INVESTMENT BETWEEN THE COMPANY AND AN AFFILIATE OF ORAMED.

ALPHA TAU ANNOUNCES APPOINTMENT OF NADAV KIDRON TO ITS BOARD OF DIRECTORS

JERUSALEM, MAY 06, 2025 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE COMPANY) (NASDAQ: DRTS, DRTSW), THE DEVELOPER OF THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY ALPHA DART, TODAY ANNOUNCED THAT CFO RAPHI LEVY WILL PRESENTATION IN THE FOLLOWING INVESTOR CONFERENCES IN MAY 2025.

ALPHA TAU TO PARTICIPATE IN MAY INVESTOR CONFERENCES

ORAMED LEVERAGES ITS STRATEGIC CAPITAL MARKETS EXPERTISE TO SUPPORT ALPHA TAU'S BREAKTHROUGH CANCER THERAPY TECHNOLOGY ACCELERATING MULTIPLE LATE-STAGE CANCER THERAPIES INCLUDING: US CLINICAL TRIALS ACROSS FOUR INDICATIONS, MANUFACTURING SCALE-UP, AND COMMERCIALIZATION EFFORTS PARTNERSHIP UNITES TWO INNOVATIVE THERAPEUTIC DELIVERY PIONEERS  ORAMED'S ORAL DRUG DELIVERY PLATFORM WITH ALPHA TAU'S PRECISION RADIATION DELIVERY TECHNOLOGY NEW YORK , APRIL 28, 2025 /PRNEWSWIRE/ -- ORAMED PHARMACEUTICALS INC. ("ORAMED" OR THE "COMPANY"), (NASDAQ: ORMP) (TASE: ORMP), A PLATFORM TECHNOLOGY PIONEER IN THE FIELD OF ORAL DELIVERY SOLUTIONS FOR DRUGS CURRENTLY DELIVERED VIA INJECTION, ANNOUNCED TODAY THAT IT HAS SUCCESSFULLY CLOSED A STRATEGIC INVESTMENT IN ALPHA TAU MEDICAL LTD. (NASDAQ: DRTS), THE DEVELOPER OF THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY ALPHA DART.

ORAMED PHARMACEUTICALS ANNOUNCES $36.9 MILLION INVESTMENT AND STRATEGIC COLLABORATION WITH ALPHA TAU MEDICAL

JERUSALEM, APRIL 28, 2025 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE COMPANY) (NASDAQ: DRTS, DRTSW), THE DEVELOPER OF THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY ALPHA DART, ANNOUNCED TODAY THAT IT HAS SUCCESSFULLY CLOSED A REGISTERED DIRECT OFFERING (THE OFFERING) WHEREBY AN AFFILIATE OF ORAMED PHARMACEUTICALS INC. (ORAMED) (NASDAQ: ORMP) (TASE: ORMP) PURCHASED 14,110,121 OF ALPHA TAU'S ORDINARY SHARES, NO PAR VALUE, AT A PURCHASE PRICE OF $2.612 PER ORDINARY SHARE.

ALPHA TAU ANNOUNCES CLOSING OF $36.9 MILLION REGISTERED DIRECT OFFERING AND STRATEGIC MARKETING ALLIANCE WITH ORAMED PHARMACEUTICALS

JERUSALEM, APRIL 02, 2025 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. (NASDAQ: DRTS, DRTSW), THE DEVELOPER OF THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY ALPHA DART, ANNOUNCED TODAY THAT THE FDA HAS APPROVED AN INVESTIGATIONAL DEVICE EXEMPTION (IDE) APPLICATION TO INITIATE A PILOT STUDY FOR THE TREATMENT OF PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM) USING THE ALPHA DART TECHNOLOGY.

ALPHA TAU RECEIVES FDA APPROVAL TO INITIATE A TRIAL FOR PATIENTS WITH RECURRENT GLIOBLASTOMA

- INTERIM RESULTS FROM THREE TRIALS EXPLORING THE USE OF ALPHA DART IN TREATING PANCREATIC CANCER SHOWING HIGH DISEASE CONTROL RATE, IMPRESSIVE OVERALL SURVIVAL IN SUB-GROUP ANALYSES, AND POSITIVE SAFETY PROFILE -

Alpha Tau Medical Ltd.

DRTS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Alpha Tau Medical Ltd.

DRTS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

DRTS